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Role of Cobalt, Iron, Lead, Manganese,
Mercury, Platinum, Selenium, and
Titanium in Carcinogenesis
by George Kazantzis*
The possible carcinogenicity of cobalt, iron, lead, manganese, mercury, platinum, selenium,
and titanium is reviewed, taking into account epidemiological data, the results of animal
experimental studies, data on mutagenic effects and on other in vitro test systems. Of the great
variety of occupations where exposure to one of these metals may occur, only haematite mining
has been clearly shown to involve an increased human cancer risk. While the possibility that
haematite might in some way act as a carcinogen has to be taken into consideration it is more
likely that other carcinogens are responsible. Certain platinum coordination complexes are used
in cancer chemotherapy, are mutagenic, and likely to be carcinogenic. Cobalt, its oxide and
sulfide, certain lead salts, one organomanganese, and one organotitanium compound have been
shown to have a limited carcinogenic effect in experimental animal studies, and except for
titanium appear to be mutagenic. Certain mercury compounds are mutagenic but none have been
shown to be carcinogenic. The presently available data are inadequate to assess the possible
carcinogenicity of selenium compounds, but a few observations suggest that selenium may
suppress the effect of other carcinogens administered to experimental animals and may even be
associated with lower cancer mortality rates in man. Epidemiological observations are essential
for the assessment of a human cancer risk, but the difficulty in collecting past exposure data in
occupational groups and the complexity of multiple occupational exposures with changes over
time, limits the usefulness of retrospective epidemiological studies.
Cobalt
Sources of Exposure
Cobalt is found in nature together with nickel and
arsenic but is more often recovered from residues
in the smelting of arsenical ores of nickel, copper
and lead. World production had increased to about
33,000 tons by 1975. The principal uses of cobalt are
in magnets, high temperature alloys, and cobalt
steels. Cobalt is used as a binder for tungsten
carbide cutting tools. A cobalt-chromium-molyb-
denum-nickel alloy, vitallium, is used in orthopaedic
surgery as an implant.
Occupational exposure to cobalt occurs principal-
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ly in the refining of cobalt, in the production of
alloys and in the tungsten carbide hard metal
industry. High exposure levels have been reported,
with a concentration of up to 79 mg/m3 in a plant
where cobalt nitrate was calcined. Adverse
respiratory effects have been reported at concen-
trations between 0.1 and 2 mg/m'. The TLV-TWA
for cobalt metal, dust, and fume (as cobalt) is 0.05
mg/m3 as a tentative value, having previously been
0.1 mg/M3.
Cobalt is present in low concentration in soil,
with an average distribution in the earth's crust of
25 mg/kg, soil concentrations varying from less than
one to 100 mg/kg. It is present in low concentrations
in drinking water (0.1-5 ,ug/l.) and in many foods, in
particular in sea foods. The average normal daily
intake is of the order of 140-580 ,ug. Cobalt is an
essential trace element in man and animals. A
cobalt-containing compound, cyanocobalamin, or
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vitamin B12 was found effective in the treatment of
pernicious anaemia, but three different cobalamins
have now been identified in the body. Vitamin B12
is necessary for growing tissue, deficiency resulting
in defective synthesis of DNA.
Cobalt as an integral part of the molecule of
Vitamin B12 is used in the treatment of megaloblastic
anaemias, and cobalt salts are also used for the
prevention of cobalt deficiency in ruminants.
Mutagenic Effects
Cobalt compounds have been shown to affect the
mitotic spindle causing C-mitosis, as have a number
of other metals (1). Herich (2) found chromosome
abnormalities in root tips exposed to cobalt nitrate.
There is some evidence from observations on
mitochondrial mutations in yeast cells, that cobalt
is able to react with DNA (3). However, no effect
has been shown on chromosomes ofhuman leukocytes
treated with cobalt nitrate (4). Cobalt chloride has
been tested for its ability to affect the accuracy of
DNA synthesis in vitro and has been shown to
decrease the fidelity of DNA synthesis by at least
30% at a concentration of 4mM (5).
Carcinogenic Effects
Experimental. Finely divided cobalt metal
powder, cobalt oxide, and cobalt sulfide, have given
rise to injection site fibrosarcoma following
subcutaneous injection, and to rhabdomyosarcoma
following intramuscular injection in rats (6, 7).
About one year after a single injection of 20 mg
cobalt oxide into rat thigh muscle, 50% of the
injected group responded with sarcomas, but mice
given doses twice as high did not develop any
malignant tumors (8). Particles from surgical
prostheses made from cobalt-chromium alloys have
been shown to be carcinogenic to rat muscle (9, 10).
Sarcomata, both at the injection site and at distant
sites have also been produced with multiple injections
of a solution of cobalt chloride in physiological saline
(11).
Clinical and Epidemiological. Although heavy
occupational exposure has occurred to cobalt
containing dusts, there have been very few reports
of cancer developing in these workers. A single
case of carcinoma of the bronchus in a worker with
hard metal disease was reported as the first recorded
case (12). In epidemiological surveys in nickel
extraction plants in the USSR, an increased mortality
from lung cancer was found in the cobalt recovery
shops as well as in the nickel processing departments.
Exposure to arsenic containing dusts was heavy,
and it is not clear to what extent the cobalt workers
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had also been exposed to nickel dusts (13, 14).
Cobalt in the occupational environment has been
declared a possible carcinogen in Germany and in
Sweden.
While wear particles from surgical prostheses
containing cobalt were found to be carcinogenic in
the rat (9), there are no convincing reports of
cancer arising in relation to such a surgical implant
in man, even though raised blood and urinary cobalt
levels have been observed in patients with vitallium
prostheses. Again, no definitive epidemiological
studies have been performed. Cobalt has been used
as a therapeutic agent in the treatment of pernicious
anaemia for close to 20 years, but again there are no
reports of cancer related to therapy.
Comments and Evaluation
Cobalt, in the form of finely divided metal powder,
the oxide and the sulphide has given rise to
fibrosarcoma and rhabdomyosarcoma in rats.
Following implantation, the metal slowly dissolves
and disappears from the injection site. Heath et al.
(15) have shown that metallic cobalt reacts slowly
with serum proteins to form soluble nondialyzable
complexes which are less toxic to rat myoblasts in
culture than the equivalent amount of ionic cobalt.
They have suggested that cobalt-protein complexes,
absorbed on the surface of myoblasts, may enter
the cell by endocytosis and that subsequent digestion
of the carrier proteins by lysosomal proteinases
leads to intracellular liberation and redistribution
of cobalt. A high proportion of intracellular cobalt
hasbeen found in the nuclei of muscle cells, more
than half of this within nucleoli, where it would be
well placed to exert an effect on DNA and RNA
replication (16). Cobalt acetate has been shown to
enhance viral transformation in embryonic cell
culture (17). There is inadequate evidence at present
to indicate that cobalt is a human carcinogen.
Research Needs
Further experimental work is required to
determine the mutagenic potential of cobalt and the
ability of the metal to induce transformation in cell
culture. Metallic cobalt together with its oxide and
sulphide are carcinogenic in the experimental
situation, briefly reported above, but it is not
known whether cobalt acts as an initiator or as a
promoter of the carcinogenic process. It would be of
interest to induce cancer in species other than the
rat, and to investigate further the carcinogenicity
of soluble compounds of cobalt.
There is a need for epidemiological studies of
cancer incidence and mortality in occupational groups
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exposed to respirable compounds and followed up
for an adequate period. Lifetime follow-up studies
would be useful of patients treated surgically with
cobalt-containing implants for the development of
cancer, together with appropriate controls.
Iron
Sources of Exposure
Iron, the most abundant metal in the earth's
crust, is found principally in the minerals haematite
Fe2O3, magnetite Fe304 and siderite FeCO3. Used
by man from ancient times, world production,
mainly in the form of steel, is now measured in
hundreds of millions of tons annually.
Iron is widely distributed in soil and water with
great variation in concentration. Soil levels range
between 7 g/kg and 550 g/kg, while in fresh water,
levels range between 0.01 and 1.0 mg/l. Ambient air
concentrations are low in rural areas, intermediate
in urban areas and highest in the vicinity of iron and
steel foundries where mean levels of up to 11 ,ug/m3
have been reported. The daily intake of iron from
the diet averages from about 9 to 35 mg per day, an
average mixed diet containing about 12-15 mg iron.
Meat, offal, eggs, and wholemeal cereals are rich,
while refined high carbohydrate diets are poor in
iron. Iron deficiency is an important cause of
nutritional ill health in industrial countries. At the
other extreme, the Bantu, who cook and brew in
iron pots, have an intake of up to 100 mg/day and
accumulate iron in the liver which may give rise to
cirrhosis.
Iron is an essential element. It is present in the
heme molecule in combination with a porphyrin, in
myoglobin, and in certain enzymes such as cyto-
chromes. In therapeutics, iron deficiency is treated
orally with a variety of ferrous salts, the sulfate,
gluconate, succinate, and fumarate being the most
common. Certain iron carbohydrate complexes,
detailed below, are given in parenteral therapy.
Occupational exposure to iron compounds, main-
ly oxides, is common in mining, iron and steel
foundry work and in arc welding. The TLV-TWA
for iron oxide fume is 5 mg/m3.
Mutagenic Effects
Iron, in common with a number of other inorgan-
ic metal compounds, has been shown to affect the
mitotic spindle, causing C-mitosis (1). Both ferrous
chloride and ferrous sulfate enhanced the transfor-
mation frequency of hamster embryo cells with
simian adenovirus (17). However, concentrations of
0.9mM or greater were required and the enhance-
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ment observed was small in contrast with other
metals showing a positive response. Ferrous chlo-
ride showed no evidence of decreased fidelity of
DNA synthesis (5).
Carcinogenic Effects
Experimental. The repeated intramuscular or
subcutaneous injection of certain iron carbohydrate
complexes, i.e., iron-dextran, iron dextrin, and
saccharated iron oxide, in large doses has given rise
to sarcoma at the injection site in rats, mice,
hamsters and rabbits (18-23). No tumors were
observed in squirrel monkeys (24), but only three
animals survived more than 44 weeks after the last
injection. The tumors obtained have been either
fibrosarcomas or histiocytic sarcomas without much
variation in histological type and characterized by
an abundance of iron containing macrophages. Iron
sorbitol, given to rats and mice under identical
conditions to those in which iron dextran was
administered, failed to produce tumors (22, 25).
The iron complex is essential for the sarcomatous
response, for neither the carbohydrate injected
alone (18, 19) nor inorganic iron compounds (26)
gave rise to sarcomas at the injection site. There is
evidence, from the experiments quoted above, of a
dose-response relationship, for while the latent
period appears to be independent of dose, both the
number of tumors and the grade of malignancy
increased with the total dose given.
The repeated intratracheal instillation in golden
hamsters of 3 mg ferric oxide suspended in normal
saline did not give rise to any tumors of the lung
(27). However, iron oxide has been shown to act in
a synergistic manner when given intratracheally to
hamsters together with benzo(a)pyrene (28, 29) and
following inhalation, together with systemically
administered diethylnitrosamine (30) when an in-
creased tumor response in the lung was observed.
A single dose of 37.5 mg benzo(a)pyrene with 12.5
mg ferric oxide produced lung cancer in 10% of
exposed hamsters compared with no tumors in
hamsters given a single dose of 50 mg ferric oxide
alone (28). It has been suggested (29) that ferric
oxide serves as a carcinogenic cofactor either by
retarding clearance of inhaled carcinogens or by
inducing cytopathological changes which make the
cells of the respiratory tract more susceptible when
exposed to carcinogens. Squamous cell carcinoma of
the lung has been obtained in rats following the
intratracheal instillation of a suspension of iron
dusts from an open hearth furnace. An increased
incidence of tumors was found when this suspension
was given with benzo(a)pyrene, explained as syn-
ergism between the iron dust and benzo(a)pyrene
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(31). In this experiment, the iron dusts were
cleansed to remove tarry materials, but a variety of
other metals were present in the dust, which
contained 52% iron with less than 1% nickel,
chromium, and arsenic.
Clinical and Epidemiological Observations. Or-
ganic complexes of iron have been given parenterally
in the treatment of iron deficiency anaemia for
nearly 30 years. Preparations used have been
principally ferric hydroxide complexed with low
molecular weight dextran (Imferon) given by deep
intramuscular injection or by intravenous infusion,
and more recently iron-sorbitol (Jectofer), iron
dextrin (Astrafer), saccharated iron oxide (Fer-
rivenin), and iron-polymaltose (Ferrum-Hausmann).
Iron dextran is now seldom given intramuscularly
because of local irritation and because attention has
been drawn to its sarcomatous potential in
experimental animals.
About 13 million doses of iron carbohydrate
complex had been administered in the first 3 years
of its use (32). Sufficient time has now elapsed for
its oncogenic potential to become apparent, but
while there has been no large-scale epidemiological
study, there is little evidence to suggest that
tumors occurring at sites where intramuscular
injections are usually given are becoming more
common.
All cases of sarcoma of the buttock were identified
from cancer registry entries in the UK over a
2-year period. Drug histories could only be ob-
tained in 90 of these (46% of total) of which four had
received intramuscular iron injections (33). Weinbren
et al. (34) reviewed the histology and clinical
reports of seven of eight published cases of tumors
developing at the site of intramuscular injection of
iron complex, including the four cases recorded by
Greenberg (33). In two of these the histology was
that of a benign rather than a malignant lesion
(including Greenberg's case 2). The tumor types in
the remaining five cases varied. Two were confirmed
as fibrosarcoma, the others were diagnosed as
reticulum cell sarcoma, rhabdomyosarcoma and
hemangiopericytoma (Greenberg's case 1). In only
two of these cases was the latent interval between
injection and the appearance of the tumor greater
than 6 years, and in one case (Greenberg's case 4)
the latent interval was only a few months. A
retrospective survey of all 72 cases of soft tissue
sarcoma presenting in a defined area over a two
year period showed no relationship with any histo-
ry of parenteral therapy (35).
An excess mortality from lung cancer has been
observed in haematite miners from a number of
countries. The original observations first reported
from Cumberland, England in 1956 (36) were
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confirmed in a further study reported in 1970 (37),
where 36 lung cancer deaths were found among
underground haematite workers compared with 21
expected from national and regional mortality figures.
There was no evidence of any excess mortality for
lung cancer among surface workers, and for iron
miners as a whole, mortality was close to the
national experience. In this study, Boyd et al. (37)
found an average concentration of radon of 100
pCi/l. in the atmosphere of the mine, and the
relationship between the level of radiation and the
excess mortality from lung cancer was comparable
to that found in other mines where radioactivity is
considered to be responsible for an excess lung
cancer mortality. An excess lung cancer mortality
was found in a group of iron-ore miners in the
Lorraine basin in France (38, 39), in the USSR (40),
in Minnesota, U.S.A. (41), and in the iron miners of
Kiruna, Sweden (42). An increased incidence of
lung cancer has also been reported in iron and steel
foundry workers from Sheffield in England (43),
where 94% of 149 subjects examined had pulmo-
nary fibrosis and 43% had tuberculosis with 16
(11%) cases of lung cancer. Exposure to polycyclic
hydrocarbons had also occurred. In a cohort study
of nearly 4000 foundry workers in Finland, the
standardized mortality rate for lung cancer was
computed at 270, taking the national figures as a
standard (44). The contribution made by cigarette
smoking could not be assessed in these studies. No
consistent increase in lung cancer has been found in
studies carried out in welders where again complex
exposures occur. Exposure to high levels of iron
oxide in the production of sulfuric acid from iron
pyrites showed, in a case-control study, no excess
of cancer of the lung or of cancer at other sites (45).
Comment and Evaluation
In their evaluation of the carcinogenicity of iron
carbohydrate complexes, the IARC (46) found the
evidence acceptable for local sarcoma production
with iron dextran in several animal species and for
iron dextrin and saccharated iron oxide in mice, but
not for iron-sorbitol-citric acid complex at the dose
rates tested. At the time of the evaluation in 1973,
only one case of sarcoma at the injection site had
been reported in man. Since then there have been
reports of a further small number of cases and two
small epidemiological studies which showed no
clear relationship between iron injections and soft
tissue sarcoma. The total therapeutic dose given
was small compared with that producing sarcoma in
animal experiments. Furthermore, in therapy iron
is given to a subject with pre-existing iron deficiency
and therefore, likely to be mobilised more rapidly
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from the injection site. The possibility that iron
dextran injections may give rise to sarcoma cannot
however, be entirely discounted, although the risk
involved appears to be very small. The IARC in
1979 (47), on the basis of the experimental animal
studies and on what they termed suggestive evi-
dence in man, classified iron dextran as "possibly
carcinogenic for humans."
In their 1972 evaluation of haematite and iron
oxide, the IARC (48) commented that iron oxide
had not been found to be carcinogenic when given
intratracheally or by inhalation to experimental
animals. Since that time, however, a number of
investigators have demonstrated a synergistic ef-
fect of iron oxide on the lung when administered
with other carcinogens.
With regard to occupational exposure, the IARC
in 1979 (47) concluded, on the basis of epidemiologi-
cal evidence, that underground haematite mining
does increase the risk of lung cancer in man, but
that the degree of evidence is inadequate to classify
haematite as a carcinogen. This increased risk
applies to underground workers only, who may also
be exposed to radon and radon daughters, other
carcinogens and to silica dust. Exposure to dusts
containing nickel, chromium or arsenic may also
occur. Concomitant exposure to carcinogenic poly-
cyclic hydrocarbons may occur in smelting opera-
tions and in steel foundries.
Public Health Implications and
Research Needs
In the present state of knowledge, exposure to
dust in haematite mining should be kept to a
minimum through the use of the most feasible and
applicable controls (49).
The animal experimental work lends credence to
the possibility that iron oxide particles can serve as
carriers for other carcinogens, and this hypothesis
requires further experimental exploration.
The role of free silica giving rise to pulmonary
fibrosis inhaled concomitantly with iron oxide re-
quires further investigation.
It is unlikely that iron oxide or any other
compound of iron could act as an initiator of the
carcinogenic process, but the possibility that a
compound in certain circumstances may act as a
promoter or potentiate the activity of another
carcinogen requires further investigation.
In epidemiological studies on iron miners, found-
ry workers, welders and other workers exposed to
iron oxide by inhalation, attempts should be made
to estimate the exposure to ionising radiation and
to other possible carcinogens.
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Lead
Sources of Exposure
Lead is extracted from several minerals, the
most abundant being galena, containing the sulfide,
but it is also found as a carbonate, sulfate, phosphate,
and chloride. Lead has been used extensively since
antiquity, total annual world production now being
of the order of 5 million tons. The major consumer
is the automobile industry, with its lead battery
and alkyllead gasoline additive. Other major uses
are in alloys, paints, printing, cables, pipes, and
glazes. Lead levels in soil may vary widely between
2 and 200 mg/kg. Lead levels in drinking water are
of the order of 0.01 mg/I., but soft water in lead
pipes or cisterns may have high levels of lead,
values of 3 mg/l having been recorded. In rural
areas the lead level in air is usually below 0.1 pRg/m3,
but this may increase to 10 ,ug/m3 and even higher
levels in urban areas with heavy traffic.
Lead is a contaminant in food and water. Total
diet studies in industrial countries indicate a daily
intake of lead of the order of 200-300 ,ug. Intake
from drinking water provides about 20 ,ug and
inhalation of city air about another 20 pug per day.
However, the total intake may be considerably
increased in soft water areas, and where food and
drink are contaminated, as from lead glazes on
ceramic tableware. Baby foods in tins may contain
lead and children may ingest lead from paint flakes
and toys. Street dust may be heavily contaminated
with lead in urban areas and very high levels have
been recorded in the vicinity of lead smelters and
mines.
Occupational exposure has been heavy in the past
in lead smelting and refining, in lead battery
manufacture and in many other industrial processes,
lead poisoning still being one of the commonest
industrial intoxications. The forms of lead most
commonly encountered are lead fume in refining
operations, lead oxide in battery manufacture and
tetraethyllead as a gasoline additive.
The TLV-TWA for inorganic lead, fume, and
dust and for lead arsenate (as Pb) is 0.15 mg/m3.
The WHO International Standard for drinking
water sets a limit of 0.1 mg lead/I., and the WHO
Provisional Tolerable Weekly Intake from food and
water is 3 mg for adults, equivalent to 0.05 mg/kg
body weight.
Mutagenic Effects
In common with a number of other metals, lead
has been shown to be capable of inhibiting the
mitotic spindle, organic compounds being particularly
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potent in this respect (1). Chromosomes in human
lymphocytes from lead workers and from children
exposed to lead have been examined by a number of
investigators (50-54), and these studies have been
recently reviewed (55). The results have been
confficting, for some studies have shown evidence
of chromosome damage and others have not done
so, even in the presence of a toxic effect. Possible
reasons for the lack of agreement could be the
mixed exposure to lead, zinc, and cadmium in some
of the groups investigated or lower exposure levels
in the groups with negative results. However,
there is also lack of agreement on the effects of lead
acetate applied in vitro to human lymphocytes in
what appear to have been carefully carried out
experiments (56, 57). The frequency of morphological
abnormalities of sperm in men with occupational
lead exposure has been observed to be positively
related to blood lead levels ranging from a mean of
23 to a mean of 75 ,ug/100 ml (58). This latter
maximally exposed group consisted of 23 workers
with evidence of lead poisoning. While such
morphological abnormalities may be related to a
reduction in fertility, they are not necessarily
indicative of genetic damage. Furthermore, the
observations have yet to be confirmed. Lead chloride
decreased the fidelity of DNA synthesis in a system
using viral DNA polymerase (5). Lead oxide enhanced
viral transformnation in hamster embryo cells, showing
intermediate activity in relation to other metals
tested (17). However, lead acetate has not been
shown to be mutagenic in the Salfnonella (Ames
test) assay for point mutations (59) nor in the
intraperitoneal host-mediated assay in mice (60).
Carcinogenic Effects
Experimental. Renal tumors have been produced
in rats following the subcutaneous injection (61) and
the subcutaneous plus intraperitoneal injection (62)
of lead phosphate. Adenoma and carcinoma of the
kidney has been observed by several investigators
(63-67) in both rats and mice following the
administration in the diet of lead subacetate and in
rats of lead acetate. Large doses of lead were used
in these experiments, which gave rise to cystic
nephritis with tubular cell damage, eosinophilic
inclusion bodies and foci of regenerating tubular
epithelium. In some instances, bilateral tumors
were observed (63). Interstitial cell tumors of the
testis have been observed in rats following prolonged
feeding with lead acetate, but the frequency of
their occurrence in control rats was not stated (64).
In a further experiment (66), adenomas of kidney,
pituitary, and prostate gland were observed. A
small number of cerebral gliomas as well as renal
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tumors have also been recorded (67). Five malignant
lymphomas developed in 41 female Swiss mice
injected subcutaneously with 0.6 mg tetraethyllead
dissolved in tricaprylin (68). However, tumors in
organs other than the kidney have not been confirmed
by other investigators, and it should be borne in
mind that lymphoma in the mouse can be of viral
origin. A cocarcinogenic effect has been postulated
for lead oxide when administered intratracheally in
hamsters together with benzo(a)pyrene (69). The
lead oxide may have acted as a carrier in this
experiment. The doses of lead salts used in the
animal experiments described above were high,
interfering with haem synthesis. Boyland et al. (63)
reasoned that carcinogenesis might have been related
to the associated porphyrinuria rather than to the
ingested lead. However, the production of porphyr-
inuria by other means did not give rise to an excess
of renal tumors, neither did the concomitant
administration of lead with other prophyrinuric
agents give rise to the excess of tumors seen with
lead acetate alone.
Syrian hamster embryo cell cultures treated with
graded doses of lead acetate showed neoplastic
transforrnation with a dose response relationship,
and these cells when injected into hamsters produced
fibrosarcomas (70).
Epidemiological. In a mortality study of lead
accumulator and other lead workers in Britain, the
men were divided into three exposure categories on
their previous urinary lead excretion. A comparison
of observed with expected deaths from all malignant
neoplasms showed no excess of cancer deaths in the
group with the highest lead exposure (71). However,
in the group with what was termed negligible
exposure (lead in urine values within the normal
range), there was a significant excess of observed
deaths from malignant neoplasms at all sites when
pensioners and employed men were taken together.
A mortality study followed over a 23-year period
was performed in the USA on a group of over 7000
workers in battery factories and smelters who were
exposed to lead for a minimum period of one year
(72, 73). Lead absorption in many of these workers
was greatly in excess of currently accepted standards.
The corrected standardized mortality ratio for all
causes was 99 for battery workers and 107 for
smelter workers, with an excess cancer mortality
from all malignant neoplasms, but seen only in
smelter workers. An excessive, but not statistically
significant mortality from cancer of the respiratory
system and of the digestive organs was seen in both
smelter and battery plant workers. In a 5-year
follow-up study of over 5000 workers from the
above cohort, this mortality pattern was not
maintained, with a small deficit in malignant
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neoplasms in smelters and a small, but significant,
excess in battery plants, largely accounted for by
malignancies of unknown primary site. The earlier
excess mortality from cancer of the digestive organs
was not confirmed, although a small excess mortality
from lung cancer was again seen. Only one renal
tumor was recorded. No internal trends with
exposure levels could be demonstrated, and this,
together with the absence of smoking histories,
where an excess of heavy smokers in the lead
exposed group could account for the relatively
small excess of lung cancer, did not support a
carcinogenic role for lead (74).
A case control study of children with Wilms
tumors of the kidney reported to the Connecticut
tumor registry explored the possibility of perinatal
exposure to carcinogenic agents. The paternal
occupation as recorded on the birth certificate was
taken as an indicator of potential exposure (75). An
association was claimed between paternal occupations
related to lead in the group developing Wilms
tumor compared with the control group. However,
the study could provide no eyidence that the
fathers with "occupations related to lead" had
actually been exposed to lead.
Comment and Evaluation
The IARC (76) accepted the evidence for the
carcinogenicity of lead acetate when given orally to
rats and mice and of lead subacetate and lead
phosphate given orally to rats, producing benign
and malignant tumours of the kidney, but commented
that the increased frequency of tumours observed
at other sites required confirmation. The IARC (77)
were unable to evaluate the significance oflymphoma
developing in Swiss mice following the injection of
tetraethyllead because ofthe propensity oflymphoma
to develop spontaneously in this strain.
The IARC in the original evaluation concluded
that there was no evidence to suggest that exposure
to lead salts causes cancer of any site in man.
However, only one epidemiological study (71) was
available at that time on workers exposed to
inorganic lead compounds and no studies to assess
cancer mortality following exposure to tetraethyl-
lead.
Since the IARC evaluation, the results of one
further epidemiological study have become available
(72, 74) but although a small excess of cancer deaths
was found, this cannot be attributed to lead exposure.
In any interpretation of the significance of the
observations on renal cancer in rats and mice fed
with lead salts it should be borne in mind that the
doses used were very high in relation to human
exposure. Rats and mice appear to be relatively
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insensitive to the toxic effects of lead and so were
able to survive the large doses given.
Public Health Implications and
Research Needs
The long history of exposure to lead, both in
occupational and general population groups with
the lack of any clinical evidence suggesting a
carcinogenic effect makes it unlikely that a high
cancer risk exists. Human sensitivity to its toxic
effects is likely to exert a protective action against
the exposure that might be necessary to give rise to
cancer, if in fact a carcinogenic potential exists for
lead.
If cancer incidence is marginally increased as a
result of lead exposure, retrospective epidemiological
studies are unlikely to be sensitive enough to show
this. As the kidney is the only organ clearly
implicated in experimental cancer, it would be
worthwhile performing case-control studies assessing
lead exposure in patients with renal carcinomas.
Follow-up studies on cancer incidence or mortality
in people with a history of childhood lead poisoning
may also be of value in determining whether lead or
its compounds can give rise to cancer in man.
The conflicting observations on the mutagenic
effects of lead should be resolved with further
carefully controlled experiments and with refinements
in techniques for assessing point mutations and
more direct observations on the capacity of lead to
damage nucleic acids.
Manganese
Sources of Exposure
Manganese is widely distributed as the twelfth
most abundant element in the earth's crust. It is
present in a number of ores, the commonest being
pyrolusite, containing the black dioxide. World
production, of the order of 7 million tons in the
1950's trebled in the 1970's. Manganese is a valu-
able metallurgical constituent, its most important
alloy being ferromanganese. The dioxide is used in
certain batteries; the permanganate has oxidising
properties and is used in disinfection.
The average manganese content of soil is be-
tween 600 and 900 mg/kg. Most drinking waters
contain less than 100 ,g/l.
Cereals may contain between 10 and 100 mg/kg and
are the main source of the element. The daily intake
in the diet has been estimated at between 2 and 4
mg but values three times as high have been
reported.
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Heavy occupational exposure has been recorded
in mines, processing and ferromanganese plants,
with air concentrations exceeding 100 mg/m3. How-
ever, concentrations above 2 mg/m3 are associated
with an increasing risk of toxic effect. The TLV
(ceiling value) for manganese and compounds is 5
mg/m and the TLV-TWA for manganese fume 1.0
mg/m3.
Manganese is an essential trace metal in a great
variety of organisms, from bacteria to plants and
mammals, and by analogy it is likely to be essential
in human metabolism although a health hazard from
manganese deficiency in man has not been confirmed.
Pyruvate decarboxylase is a manganese metallo-
enzyme and several other important enzymes are
manganese dependent. Manganese appears to have
a role in carbohydrate and lipid metabolism, in
embryonic development, growth and brain function.
Mutagenic Effects
Manganese was first considered to be a bacterial
mutagen as far back as 1951 (78).
There is evidence that manganese is able to react
with DNA. Antibiotic resistant mutants (79) and
petite mutations have been observed in yeast cells
treated with manganese, indicative of a mutation
effect on mitochondrial DNA (80). These authors
suggested that manganese acts as an error produc-
ing factor on replicating mitochondrial DNA, by a
direct action on mitochondrial DNA polymerase.
Manganese has been shown to reduce the fidelity of
DNA synthesis in vitro. Substitution of manganese
for the magnesium ion resulted in an increase in
misincorporation by bacteriophage T4 DNA
polymerase (81) and by avian virus DNA polymerase
(82). Manganese chloride in a system using avian
virus DNA polymerase decreased fidelity of DNA
by at least 30% with increased error frequency and
diminished synthesis (5). Enhanced viral transfor-
mation of hamster embryo cells was demonstrated
with manganese chloride, which showed intermediate
activity compared with other metals which were
tested (17). Mutations induced by the manganous
ion in bacteriophage T4 have been shown to be
reversible by 2-aminopurine and thought to be of
the transition type (83).
Carcinogenic Effects
Experimental. Lymphosarcomadeveloped after
18 months in 67% of a group of DBA mice treated
with manganese chloride compared with 24% in a
control group (84). Rats and Swiss albino mice were
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dosed with pure manganese powder, manganese
dioxide or manganous acetylacetonate suspended in
trioctanoin (85). The rats were given intramuscularly
total doses of 90 mg, 90 mg and 300 mg, respective-
ly, and by gavage 240 mg in multiple treatments.
The mice were given total doses of 10 mg, 15 mg
and 30 mg respectively, intramuscularly only. No
difference in tumor incidence was noted between
treated and control animals with regard to manga-
nese powder and manganese dioxide. In contrast, a
statistically significant number of fibrosarcomas (19
tumors in 50 rats) developed at the injection site in
the rats given manganous acetylacetonate, with a
mean latent interval of 17 months. The author
commented that manganous acetylacetonate sus-
pended weli in the vehicle, its reaction, therefore,
not fitting the hypothesis of Brand et al. (86) for
foreign body carcinogenesis.
There is some evidence that in certain situations
manganese may be able to suppress the response to
an administered carcinogen. Thus, manganous ace-
tate decreased the yield of hepatomas following the
administration of dimethylaminoazo benzene (87).
The incidence in injection site sarcoma in rats
receiving nickel subsulfide either alone or in combi-
nation with equimolar amounts of aluminium, cop-
per or chromium dusts was 96-100%. However, in a
group of rats given an equimolar amount of manga-
nese dust, the incidence of sarcoma fell to 63%. In a
further experiment, 5 ,umole nickel subsulfide given
intramuscularly with 20 ,umole manganese powder
reduced the tumor incidence from 12 out of 15 rats
given nickel subsulfide with chromium dust, to 1
out of 15 (88). The hypothesis was propounded that
manganese may antagonize nickel inhibition of
RNA polymerase activity.
Clinical and Epidemiological. There are no
clinical reports implicating manganese as a human
carcinogen. Epidemiological studies have been per-
formed on manganese miners and other occupation-
al groups with the aim of eliciting information on
the neurotoxic and pulmonary effects of manganese
exposure, and these have been summarised (89).
There are as yet no epidemiological studies which
have attempted to relate manganese exposure to
cancer mortality or incidence.
Evaluation
There is accumulating evidence for the muta-
genicity of manganese. There is some evidence that
one organo manganese compound, manganous
acetylacetonate, can give rise to injection site sar-
coma in rats. There is no evidence at present for a
carcinogenic effect of manganese in man.
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Research Needs
Further work is required to determine the poten-
tial of manganese in giving rise to point mutations
and in inducing transformation in cell culture. Work
on experimental carcinogenesis with manganese
compounds is lacking. In epidemiological studies on
occupational and other groups with manganese
exposure attention should be directed to estimation
of the cancer risk.
Mercury
Sources of Exposure
Mercury is found in nature mainly as a sulfide, in
low concentration in the earth's crust except for
rich focal deposits where it may also be present in
metallic form. Mercury is a fairly volatile element
which is released into the atmosphere and deposited
again to form a natural global cycle estimated as at
least 30,000 tons a year. Annual world production is
of the order of 10,000 tons and industrial activities
involving mercury, together with the combustion of
fossil fuels, adds a man made cycle to the above.
The chloralkali industry is the largest consumer,
followed by the electrical and paint industries,
measuring instruments, agriculture, dentistry and
the chemical industry. Organo mercurials have
been widely used as fungicides in the wood pulp and
paper industries, in paints and in seed dressings.
Soil levels of mercury are low, of the order of 50
,ug/kg and uptake by plants is low, even where seed
dressings have been applied. Uncontaminated water
also has a low level of mercury, below 1 ,ug/l., and
except for the vicinity of mines and industrial
emissions, air levels in urban areas are of the order
of 50 ng/m3.
Mercury is a food contaminant which has been
extensively studied, with an average daily intake in
the UK of 5 to 10 ,ug total mercury. However,
mercury in the aquatic environment, from natural
sources or resulting from human activity, can be
methylated by microbial action and concentrated in
food chains. Fish may, therefore, have high levels
most of which is methyl mercury. The average
intake of methyl mercury from fish is of the order of
2 ,ug/day, but fish eaters may ingest 20 ,g/day and
the consumption of fish from contaminated waters
has given intakes of up to 5000 ,ug/day.
Occupational exposure occurs most commonly to
metallic mercury vapor, but also to a variety of
inorganic mercury compounds as aerosols and to
alkyl mercurials.
Poisoning following exposure to metallic mercury
vapour has been common in the past. The TLV-TWA
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for mercury vapor and all mercurial compounds
except alkyl mercurials (as Hg) is 0.05 mg/m3. For
alkyl mercurials this figure is 0.01 mg/m3. The
WHO upper limit for mercury in drinking water is 1
,ug/l. TheWHO Provisional Tolerable Weekly Intake
is 0.3 mg total mercury, of which not more than 0.2
mg should be present as methylmercury.
Mutagenic Effects
Mercury compounds produce a variety of effects
on the genetic material, the organic being more
active than inorganic compounds. These mutagenic
effects have been reviewed by Ramel (90). Mercury
in common with a number of other metals can
damage the mitotic spindle giving rise to C-nitosis.
Alkylmercury compounds have been shown to be
particularly potent in this respect, methylmercury
being even more potent than colchicine. All mercury
compounds tested on root tip cells of Allium cepa
induce polyploidy and other deviating chromosome
numbers in the cell. Nondisjunction and sex-linked
recessive lethals have been produced in Drosophila
melanogaster following feeding of the larvae with
Ceresan-M (91). Chromosome abnormalities have
been produced in animal and human cell cultures
and these have been briefly reviewed by Leonard
(92).
Skerfving (93) observed dose-related chromosome
aberrations in lymphocytes of consumers of
methylmercury-contaminated fish. They found a
significant increase at blood methylmercury levels
of around 100 ,ug/l., of aneuploidy, unstable
chromosome type aberrations and of cells with
chromatid type aberrations. An increase in human
lymphocyte chromosome aberrations following both
in vivo and in vitro exposure to methyl mercury has
also been demonstrated by Kato and Nakamura
(94). In the Iraq epidemic, lymphocyte cultures
showed no significant difference in chromosomal
aberrations between exposed and control subjects.
However, in Skerfving's study the duration of
exposure was long, from 3 to 20 years, while in Iraq
the total exposure was limited to a few months (95).
Verschaeve et al. (96) found chromosome aberrations
and increased aneuploidy in methylmercury-exposed
workers but did not report exposure levels.
These results provide support for the hypothesis
that exposure to organomercury compounds may
result in genetic damage to human somatic cells.
However, while mercury is distlibuted to mammalian
gonads, there is no good evidence that damage to
germ cells has been produced. Ramel's (97)
experiments provide evidence that organic mercurials
can cause genetic alterations by two different
mechanisms, one resulting in chromosome aberrations
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and one in chromosome loss following spindle
inhibition.
Carcinogenic Effects
Experimental. In spite of its undoubted
mutagenic potential on eukaryocytes, mercury and
its compounds do not appear to be oncogenic.
Druckrey (98) reported spindle-shaped sarcomas
containing fine droplets of mercury in the abdominal
muscles of rats two years after intraperitoneal
injection of metallic mercury.
Mercuric chloride was able to enhance viral
transformation in hamster embryo cell cultures at a
concentration of0.05mM, thus showing internediate
activity together with cobalt, lead and manganese
also considered here (17).
Clinical and Epidemiological. There are no
convincing clinical reports or any epidemiological
studies which suggest that any form of cancer in
man may be related to exposure to either inorganic
or organic mercury compounds.
Comment and Evaluation
Inorganic and especially organic mercurials have
been demonstrated to give rise to chromosome
damage in experimental systems, and long-term
exposure to methylmercury has been shown to give
rise to somatic chromosome abnormalities in man.
There is no indication that mercury or its compounds
are human carcinogens. It may be that mercury
compounds are too toxic to permit sufficient exposure
in either animals or man to reveal a carcinogenic
effect.
Research Needs
There is little known concerning the interaction
of mercurial compounds with nucleic acids. The
mutagenic activity of mercurial compounds needs
further testing in mammalian systems. Should the
chromosome abnormalities seen in human somatic
cells following exposure to methylmercury also
occur in germ cells, individuals with inherited
chromosomal defects would be more likely to develop
malignant disease. Such inherited chromosome
aberrations should be looked for.
Platinum
Sources of Exposure
Platinum is present in the earth's crust in very
low concentrations, alloyed with other metals in
Group VIII of the periodic table. The richest source
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of platinum containing minerals is found in South
Africa, but even here the concentration of platinum
is no greater than 10 ppm. Total world production
of the platinum group metals in 1975 was of the
order of 170,000 kg. Platinum has many uses
related to its catalytic properties and its resistance
to corrosion and oxidation; and some derivatives
have recently been found to have a limited use in
cancer chemotherapy.
Only a few measurements of platinum concen-
trations in the environment have been reported. No
measurable amounts of platinum have been found in
soil, water or. ambient air samples in the USA
except in precious metal refineries. Here air
concentrations between 0.16 and 0.38 ,ug/m3 were
recorded. Soluble salts of platinum (as Pt) have
been assigned a TLV-TWA of 0.002 mg/m3. The
introduction of catalytic converters containing the
platinum group metals to remove pollutants from
automobile exhausts has provided a new source of
environmental contamination, in particular in the
vicinity of highways. The maximum accumulation
of small particles of platinum group metals in the
atmosphere in a "worst case" situation would not,
according to a U.S. study (99) exceed 0.06 ,ug/m3.
Similarly, the concentration of platinum in the top
soil adjacent to a highway with heavy traffic was
not expected to exceed 0.008 ppm after a period of
ten years.
Biochemical and Toxicological
Considerations
The six metals in the platinum group are nontoxic
and nonallergenic in their metallic states. The
complex salts of platinum, but not of the other
metals in the group, act as powerful sensitizers,
ammonium hexachloroplatinate and hexachloroplatinic
acid being particularly potent in this respect (99).
Allergenicity appears to be related to the number
of chlorine atoms present in the molecule, but other
soluble platinum compounds are also active.
Some ionic derivatives can react selectively with
specific chemical sites in proteins such as disulfide
bonds and terminal-NH2 groups, with functional
groups in amino acids, and in particular with
receptor sites in nucleic acids. These compounds
exhibit neuromuscular toxicity and nephrotoxicity.
Neutral complexes of platinum, such as cis-
dichlorodiammine platinum (II) and analogs have
the property of inhibiting cell division and have
antibacterial activity. Some of these have antitumor
activity: cis-dichlorodiammine platinum (II); cis-
tetrachlorodiammine platinum (IV); dichloroethylene-
diammine platinum (II); oxalodiammine platinum
(II); malonatodiammine platinum (II); cis-dichloro-
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bis(ethyleneimine) platinum (II); cis-dichlorobis(cy-
clohexylamine) platinum (II); and 1,2-dinitratodi-
(a)mminecyclohexane platinum (II).
To have antitumor activity, the complexes should
be neutral and should have a pair of cis leaving
groups. Other metals in the group give complexes
which are inactive or less active than the platinum
analog. The antitumor activity of these square-
planar complexes is stereospecific, for whereas the
cis complexes are active, the corresponding trans
forms are inactive. This is believed to be due to
stereoselectivity of the biochemical reaction within
the cell, and not to differences in metabolism or
availability. Two cis-monodentate or one bidentate
leaving group is required, the rate of exchange of
the leaving groups should be neither too low nor too
high and should fall into a restricted "window of
lability" centered roughly on that of the chlorides,
and the ligands trans- to the leaving groups are
preferentially strongly bonded, relatively inert amine
systems (100, 101).
At therapeutic dosages, these complexes produce
severe and persistent inhibition of DNA synthesis
with little inhibition of RNA and protein synthesis.
The transport of DNA precursors through the
plasma membrane is not inhibited and neither is
DNA polymerase activity. It is believed that the
platinum complexes react directly with DNA (102).
They react both monofunctionally and bifunctionally
with active sites on the bases, being mainly localized
in regions of the DNA that are rich in guanosine
and cytosine. Some 80% of an injected platinum
complex is rapidly excreted in the urine and there
does not appear to be selective uptake in tumor
tissue. The mechanism of action of these complexes
has been further reviewed (99, 103).
Mutagenic Effects
The fortuitous discovery that cetin coordination
complexes of platinum had the property of inhibiting
cell division in E. coli but not cell growth (104) led
to intensive investigation of the group of compounds
in view of their potential as antitumor agents. Most
observations have been performed with cis-
dichlorodiammine platinum (II) (cis-DDP). A strong
mutagenic effect of cis-DDP has been demonstrated
in bacterial test systems, both with E. coli (105)
and Salmonella (106). The strain of Salmonella used
is known to be specifically reverted by base-pair
substitution mutagens. Cis-DDP has been shown to
forn both intra- and interstrand crosslinks with
human DNA in cultures of HeLa cells (107), this
crosslinkdng effect being probably due to the structure
of the whole molecule rather than to its metal
component. Two analogs of cis-DDP, cis-dichloro-
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biscyclopentylamine platinum (II) and cis-dichloro-
bispyrollidine platinum (II), have also been shown
to be mutagenic without microsomal activation in
the Ames test but less active than cis-DDP. Cis-DDP
has been shown to induce the growth ofbacteriophage
from lysogenic strains of E. coli (108). From these
observations Reslova was able to show a correlation
between the antitumor activity of cis-DDP and its
ability to bind DNA and induce phage from bacterial
cells.
Cis-DDP has been shown to cause chromosome
aberrations in cultured hamster cells (109, 110) and
also a significant, dose-dependent increase in sister
chromatid exchanges, the increase in exchange
frequency being more than 3-fold at a concentration
of 1.0 jig Pt/ml (110). These authors were able to
demonstrate a point mutation effect with the induction
of 6-thioguanine-resistant mutants in a dose-
dependent manner, the potency of cis-DDP being
comparable to that of benzo(a)pyrene. In addition,
morphological transformation of hamster embryo
cells was obtained with concentrations of 0.1 to 0.25
,ug Pt/ml. Enhancement of viral transformation of
hamster embryo cells was produced at a concentration
of less than 0.05mM platinum together with anti-
mony, arsenic, cadmium, and chromium showing
the highest activity in this respect (17).
Attention should be drawn to the technique of
performing certain mutagenicity assays using
dimethyl sulfoxide as the vehicle, cis-DDP reacts
with dimethyl sulfoxide so that not more than 20%
of the original complex is present after 2 hr. The
solvolysis of cis-DDP in dimethyl sulfoxide has
been monitored by nuclear magnetic resonance
(111).
Antitumor and Carcinogenic Effects
Experimental. Cis-DDP is active in mice and
rats against a variety of tumors induced by chemical
or viral agents. Administration has resulted in
cures or significant regression in animals with
sarcoma, leukemia, and other neoplasms, and many
results have been reported (99). In contrast, there
have been few observations published on the possible
carcinogenic activity of the platinum coordination
complexes.
In a well controlled study, cis-DDP has been
shown to significantly increase lung adenoma
frequency and to give rise to skin papillomas and
carcinomas in mice (112). Cis-DDP administered
intraperitoneally weekly over 10 to 19 weeks in a
total dose of 32.5 mg/kg increased the adenoma
frequency from 0.5 to 0.8 adenoma/mouse to 10 to
16 adenomas/mouse after 8 months. Administered
in the same way, in a total dose of 25.9 mg/kg,
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cis-DDP together with topical applications of croton
oil produced skin papillomas in half the survivors at
41 weeks, with epithelioma in three mice by the end
of the year. Groups of 20 rats were given six weekly
subcutaneous injections of cis-dichlorobiscyclopen-
tylamine platinum (II) (DCP) or cis-dichlorobispyr-
rolidine platinum (II) (DPP) in trioctanoin. Six and
three rats, respectively, developed sarcomata at
the injection site, a further two (DPP) rats and one
(DCP) rat developed metastasizing sarcoma in the
abdominal cavity without sarcoma at the injection
site, and one (DPP) rat developed an epidermal
carcinoma of Zymbal's gland. There were no skin
papillomas, epitheliomas, or sarcomas in the control
animals. Cis-PDD being moderately water soluble
would be unlikely to be retained at the injection site
and so was not tested for sarcoma induction. Its
two derivatives are much less water soluble which
would result in poorer delivery to peripheral tissues.
Cis-DCP also increased adenoma frequency in the
mouse, but at a much lower rate than cis-DDP. The
authors considered cis-DDP to be a moderately
active carcinogen and rather more active than ethyl
carbamate, with which they made an experimental
comparison.
Clinical and Epidemiological. Chemotherapy
with cis-DDP usually in combination with other
drugs has produced significant regression in testicular
and ovarian tumors, in some cancers of the head
and neck and in certain lymphomas. Cancers of the
gastrointestinal tract and of the breast appear to be
refractory to treatment with cis-DDP. There are no
reports of cancer related to occupational exposure
to platinum compounds. No epidemiological study
of cancer mortality or incidence in platinum workers
has been reported. However, because of the high
risk of intractable sensitization to soluble salts of
platinum, workers have been monitored for health
effects for many years and exposure to platinum
has been strictly controlled at very low levels.
Comment and Evaluation
The experimental evidence indicates that certain
platinum coordination complexes are electrophilic
reactants and direct acting mutagens. On theoretical
grounds these complexes would be expected to act
as initiators of the carcinogenic process. In a single
series of reported experiments the results support
the hypothesis (112), for the adenoma frequency in
the strain of mouse employed is known to be a good
indicator of carcinogenic activity. Skin papilloma
and epithelioma production following the application
of croton oil as promoting agent again supports the
hypothesis
The use of platinum coordination complexes in
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cancer therapy may expose the recipient to a
further risk ofcancer should a sufficient prolongation
of life span be attained. This pattern of activity
would be consistent with that of other electrophilic
reactants, such as the alkylating agents used in
cancer chemotherapy.
There is no evidence to suggest an increased
cancer risk following occupational exposure to
platinum compounds. The low exposure levels
consistently maintained in the occupational environ-
ment make such a possibility unlikely.
Research Needs
The carcinogenic activity reported for the platinum
coordination complexes requires confirmation and
further study in appropriate animal models. There
is currently considerable research activity in progress
on these complexes in view of both their practical
chemotherapeutic and theoretical importance.
Selenium
Sources of Exposure
Selenium is found mainly in the form of various
metallic selenides usually associated with sulfide
ores from which it is extracted as a by-product. In
soil it is also present as basic ferric selenite and
calcium selenate. World production is of the order
of 1500 tons per annum, its principal uses being in
electronics, in the glass, pigment, rubber, and
chemical industries. Soil concentrations vary from
0.1 to over 1000 mg/kg, from deficient to seliniferous
areas, with commonly found values between 1 and
10 mg/kg. Some plants, including cereals and grasses
concentrate selenium from the soil and give rise to
poisoning in grazing animals. Selenium levels in
drinking water rarely exceed 10 jug/l., but high
values have been found in some alkaline waters.
The average daily intake of selenium in food and
water varies widely in different countries, from 60
,ug/day to 300 p.giday. A low selenium intake in a
broad selenium deficient belt in China has been
associated with Keshan disease, an endemic juvenile
cardiomyopathy (113).
Occupational exposure to selenium may occur in
copper refineries, where the first case of poisoning
was recognized, in rectifier production plant and in
various industries using selenium. Levels between
40 and 400 %gmg/m3 have been encountered, but
few environmental measurements have been
reported. The TLV-TWA for selenium compounds
(as Se) is 0.2 mg/m3.
Selenium is an essential trace element in several
animal species and is added to foods in selenium-
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deficient areas. Its role in human metabolism is
obscure. It is associated with -SH groups in proteins
and has a metabolic relationship with the tocopherols.
Selenium compounds and the tocopherols are
antioxidants which may help to maintain cellular
stability by inhibiting oxidation of lipids in cell
membranes. The element is an essential component
of glutathione peroxidase and has a role in ubiquinone
biosynthesis. The toxicology of selenium has been
recently reviewed (114, 115).
Mutagenic Effects
Nakamuro et al. (116) observed dose related
chromosome aberrations in cultured human leukocytes
treated in vitro with a number of selenium
compounds, selenites being more active than
selenates. Most of the aberrations were chromatid
gaps, but an increase in chromatid breaks and
exchanges was also observed. Rec assay using B.
subtilis with different recombination capacities,
and observation of a loss of transforming activity of
B. subtilis DNA, indicated that substantial damage
to DNA had been produced. Other authors (4)
failed to obtain changes in human leukocytes, but
the reason for this may have been the low doses
employed. However, Shamberger et al. (11 7) reported
a significant reduction in chromosome breakage
induced by dimethylbenzanthracene in cultured
human lymphocytes treated with selenite.
Carcinogenic Effects
Experimental. Long-term feeding experiments
with both selenites and selenates have been performed
in rats and mice. The initial study performed in rats
showed an increased incidence of nonmetastasizing
liver tumors which occurred only in association
with cirrhosis (118) and a later study showed a
small number of hepatomas and adenomas (119). In
a detailed study (120) in which the dietary pattern
of selenium was varied as well as the selenium
content, a similar number of tumors was found in
both experimental and control groups, but with no
liver tumors, and it was concluded that selenium
was not related to tumor occurrence. In a study by
Schroeder and Mitchener (121) a significant increase
in a variety of tumors was found in the treated
group, but again none involved the liver. The
treated rats lived longer than the controls and the
results are thus difficult to evaluate. In a second
study by the same investigators (122), on mice, no
increase in tumor incidence was found. Hepatomas
were also induced by feeding mice with the fungicide
selenium diethyl dithiocarbamate, initially by gavage
and subsequently by addition to the diet (123).
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While a significant increase in the incidence of
tumors was found in the exposed mice, similar
results were obtained in mice given a selenium free
dithiocarbamate.
To complicate the assessment of the role of
selenium as a possible carcinogenic agent, a number
of studies have demonstrated an inhibitory effect of
selenium on tumor yield in rats and mice following
the administration of standard carcinogens. This
effect has been observed following both local
application and selenium enrichment of diets. Thus
sodium selenide applied with croton oil or sodium
selenite given in the diet decreased the skin tumor
incidence following painting with dimethylbenzan-
thracene (124) and a similar effect was seen following
skin application of benzo(a)pyrene after feeding
with sodium selenite (125). Rats fed 2-acetylamino-
fluorene showed mammary carcinoma and hepatoma
inhibition which appeared to be related to selenium
concentration in the diet (126). A 50% reduction in
the yield of liver tumors in rats given dimethyl-
aminobenzene with 5 ppm sodium selenite added to
the diet had been observed much earlier (127).
Furthermore, the addition of selenium oxide to
drinking water at a rate of 2 mg/l appeared to lower
the incidence of spontaneous mammary tumors in a
group of virgin mice (128). Further details of these
and other experiments including dose rates, are
given in reviews by Fishbein (114) and IARC (129).
Epidemiological. In a study of 300 workers
exposed to selenium in a rectifier plant over a
period of up to 26 years, no increase in cancer
mortality was found when compared with expected
rates (130). There were six cancer deaths from
different sites where 5.1 were expected, but the
completeness of ascertainment of the mortality
data is not known. There are no other epidemiological
data on cancer mortality in occupationally exposed
groups known to the author.
Shamberger and his colleagues have carried out
epidemiological studies in general population groups
in the U.S., comparing total cancer mortality and
mortality from cancer at various sites in high and
low seleniferous areas, based on selenium content
of forage crops and of human blood (131). A high
negative correlation was found between blood
selenium levels and age specific cancer death rates.
In a further study in which high and low selenium
urban areas were matched (132) mortality was
lower, in high selenium areas, from cancer at a
number ofsites, including lymphoma, gastrointestinal,
respiratory, and, in the female, breast and
reproductive organs. Similar inverse correlations
were observed between both dietary selenium
intake and selenium levels in whole blood and
cancer mortality patterns in different countries
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(133). Blood selenium levels in patients with certain
cancers, in particular of the gastrointestinal tract
and with Hodgkin's disease were found to be
significantly lower than in control patients with
other diseases (134), but this lower blood selenium
level may of course have followed and not preceded
the cancer.
Comment and Evaluation
The IARC (129) considered the available data in
animals insufficient to allow an evaluation of the
carcinogenicity of selenium compounds. They
considered the data in man to provide no suggestion
that selenium is carcinogenic. The IARC commented
further that the evidence for a negative correlation
between regional cancer death rates and environ-
mental selenium levels is not convincing. With
regard to the early animal experimental work,
hepatic tumors were obtained only in rats with
pre-existing cirrhosis resulting from selenium toxicity,
they did not metastasize and the observation has
not been repeated in the same or other species.
There are also difficulties in interpretation of the
data from the other experiments on carcinogenesis
quoted above. There is some consistency in the
observations on an apparently antagonistic effect of
selenium towards the induction oftumors in different
organs by a number of carcinogens.
In man there are no epidemiological or clinical
data to suggest that any selenium compound may
be carcinogenic, but there is one small study only,
with negative results. The observations on a negative
correlation between cancer mortality and selenium
levels in the natural environment have to be
interpreted with caution. Blood selenium levels did
not correlate well with environmental assessments
of high and low selenium areas (134). The lack of
congruence between these areas and regional cancer
statistics meant that arbitrary classifications had to
be made which were not always supported by the
data on selenium level in the environment, as a
result of which the association has been judged to
lack strength and consistency (135).
Research Needs
More information is required on the mutagenic
activity of selenium compounds, both with regard
to their ability to produce chromosome abnormalities
and to produce mutations in bacterial systems. The
activity of selenium compounds in inducing
transformation in cell culture requires investigation.
The status of selenium as a possible electrophilic
reactant requires investigation. As one possibility,
abnornal methylation of nucleic acids by a compound
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such as adenosylselenomethionine may occur (136).
Carefully controlled work is required on experimental
carcinogenesis with selenium compounds.
The paucity of epidemiological data on cancer
mortality and incidence in groups with occupational
exposure to selenium compounds is striking.
The possibility that selenium may prevent some
forms ofhuman cancer from developing, perhaps by
inactivating a more potent carcinogen, requires
further investigation.
Titanium
Sources of Exposure
Titanium is widely distributed in the earth's
crust, where it is the eighth commonest element. It
has many uses, with an annual production of over
1-1/2 million tons. Titanium alloys include surgical
implants which resist corrosion by body fluids and
ferro titanium used in the steel industry. The
dioxide is extensively used as a white pigment in
paint, paper and plastics. It is also used in food as a
colouring agent, in cosmetics and in pharmaceuticals.
Other titanium compounds are used as catalysts.
Titanium concentrations in drinking water range
between 0.5 and 15 ,ug/l. Many vegetables and
cereals contain high levels of titanium. The daily
intake from dietary sources has been estimated at
between 0.3 and 2 mg of the element. Occupational
exposure may may be heavy and concentrations in
air up to 50 mg/m3 have been recorded. Titanium
dioxide has been classified as a nuisance particulate,
with a TLV of 10 mg/m3. Titanium is poorly
absorbed from the gut, and no essential metabolic
role has yet been ascribed to this element.
Mutagenic Effects
Titanium nitrate, while not giving rise to C-
mitosis in root cells of Allium cepa, did however
induce sticky chromosomes manifested mainly by
the formation of anaphase bridges (1). Abnormal
staining of the chromosomes at metaphase-anaphase
was also seen.
Carcinogenic Effects
Titanium dioxide, together with ferric oxide
considered in this paper, did not produce trans-
formation of Syrian hamster embryo cells in culture,
even though concentrations as high as 20 ,ug/ml of
medium were used (137).
Experimental. Titanium oxalate or acetate given
in drinking water at a rate of 5 mg (Ti)/l to 150 mice
of both sexes for their whole life span from weaning,
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produced no increase in tumor frequency or other
adverse effect compared with control animals (138).
In a long-term feeding study performed by the
National Cancer Institute (139), rats and mice
given titanium dioxide under their standard bioassay
protocol experienced no increase in cancer. Inbred
Fischer rats were injected intramuscularly at monthly
intervals with 200 mesh fine titanium metal powder
suspended in 0.2 ml trioctanoin to a total dose of 39
mg in male rats and 23 mg in female rats, and
observed over a period of 820 days (140). 2/50 rats
developed fibrosarcoma and 3/50 rats developed
lymphosarcoma. There were no such tumors in an
equal number of control rats injected with the
vehicle or in groups of rats injected similarly with
powdered copper or iron, but tumors were obtained
with powdered nickel and a few tumors with
powdered chromium. The organic compound
titanocene, dichlorodicyclopentadienyl titanium
suspended in trioctanoin and injected intramuscularly
in rats and mice has also given rise to injection site
fibrosarcomas and some animals developed hepatoma
and malignant lymphoma of the spleen but details
were not given (141).
Clinical and Epidemiological. Titanium-
containing alloys used as surgical implants have not
been associated with cancer or other adverse effects
following long term contact with tissues. Heavy
long-term occupational exposure to titanium dioxide
dusts has not given rise to ill effects or been
associated with cancer. There are no epidemiological
studies in workers with heavy past exposure to
titanium containing dusts.
Comment and Evaluation
The data are insufficient for an evaluation of the
carcinogenic activity oftitanium. Titanium compounds
appear to be biologically inert. Mutagenic activity
has not been investigated except for a minimal
effect on chromosomes in a single experiment. Cell
transformation has not been observed. The tumor
yield was small in Furst's experiment (141), but the
results cannot be dismissed, as copper and iron
injected in the same way produced no tumors at all.
There is no evidence to suggest that titanium
compounds have acted as human carcinogens.
Conclusion
The eight metals considered above have little in
common, except for some evidence that they, in one
form or another, can give rise to genetic damage or
to experimental cancer. Of the great variety of
occupations where exposure to one of these metals
may occur, only haematite mining has been shown
to involve an increased human cancer risk, raising
the possibility that haematite might in some way
act as a carcinogen or potentiate the activity of
another carcinogen. The stimulus of therapeutic
application in anticancer therapy led to intensive
investigation of platinum coordination complexes,
and as a result, although observations on experimental
carcinogenesis are at present scanty, these complexes
fit the model of compounds that bind to cellular
nucleophiles which are direct acting mutagens and
also capable of cancer initiation. Cobalt has given
rise to injection site cancer and lead to renal cancer
in animal studies, following ingestion in large
doses, and both metals show evidence of mutagenic
activity. One organotitanium and one organoman-
ganese compound, again in large doses have pro-
duced a small yield of injection site tumors, but only
the latter appears to be mutagenic. Some mercury
compounds produce genetic damage, but have not
given rise to cancer. The role of selenium remains
enigmatic. Metals as mutagenic initiators of cancer
have been further considered by Flessel (142).
A carcinogenic potential for these metals does
not in itself imply an increase in human cancer risk.
Length, intensity and route of exposure together
with the physical and chemical form of the metal
are some of the factors which act as determinants of
outcome. Epidemiological observations are essen-
tial for the assessment of human risk. While consid-
erable progress has been made in developing
laboratory tests for the prediction of carcinogenic
activity, there is as yet no systematic approach to
the recording and collection of epidemiological data
in the occupational environment. Past employment
records are, in practice, often destroyed after a
minimal period and exposure data, or even a record
of jobs done may be nonexistent. At the least, it
should be obligatory for employment records to be
retained, if possible in a standard forn. Occupa-
tional exposures are often multiple, with more than
one possible carcinogen being involved, and both
the nature of the industrial process and exposure
levels may change over the years. For research
purposes, a cumulative occupational record com-
piled for a sample of a selected workforce and
linked to mortality records and cancer registration
would be of inestimable value.
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